Inclusion body myositis: Old and new concepts

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 11, 2009, Pages 1186-1193

  Amato, A A ^a   Barohn, R J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTINUCLEAR ANTIBODY; ARIMOCLOMOL; AZATHIOPRINE; BETA INTERFERON; CYCLOSPORIN; ETANERCEPT; HLA DR3 ANTIGEN; IMMUNOGLOBULIN; LITHIUM; METHOTREXATE; OXANDROLONE; PLACEBO; PREDNISONE; TACROLIMUS;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ELECTROPHYSIOLOGY; FLEXOR MUSCLE; HISTOPATHOLOGY; HUMAN; INCLUSION BODY MYOSITIS; MONOCLONAL IMMUNOGLOBULINEMIA; MUSCLE ATROPHY; MUSCLE BIOPSY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; QUADRICEPS FEMORIS MUSCLE; RATING SCALE; REVIEW; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE;

AMYOTROPHIC LATERAL SCLEROSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; PROGNOSIS; PROTEOMICS;

EID: 70349658621     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.173823     Document Type: Review

References (102)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;3251487-98
2. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: Clinical and pathological boundaries. Ann Neurol 1996;40:581-586 (Pubitemid 26357882)
3. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurol Clin 1997;15:615-648
4. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-631 (Pubitemid 46921056)
5. Amato AA, Russell J. Neuromuscular disease. New York: McGraw-Hill, 2008:681-719
6. Lotz BP, Engel AG, Nishino H, et al. Inclusion body myositis: observation in 40 patients. Brain 1989;112:727-747 (Pubitemid 19151167)
7. Mhiri C, Gherardi R. Inclusion body myositis in French patients. A clinicopathological evaluation. Neuropathol Appl Neurobiol 1990;16:333-344
8. Badrising UA, Maat-Schieman ML, van Houwelingen JC, et al. Inclusion body myositis: clinical features and clinical course of the disease in 64 patients. J Neurol 2005;252:1448-1454 (Pubitemid 41803832)
9. Barohn RJ, Amato AA. Inclusion body myositis. Curr Treat Options Neurol 2000;2:7-12.
10. Griggs RC, Askansas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-713
11. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347
12. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-407
13. Bohan A, Peter JB, Bowman RL, et al. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977;56:255-286 (Pubitemid 8130612)
14. Briemberg HR, Amato AA. Dermatomyositis and polymyositis. Curr Treat Options Neurol 2003;5:349-356
15. van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-321
16. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004;14:337-345
17. Badrising UA, Maat-Shieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000;55:1385-1387 (Pubitemid 30829385)
18. Lindberg C, Persson LI, Bjorkander J, et al. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994;89:123-131 (Pubitemid 24095268)
19. Wilson FC, Ytterberg SR, St Sauver JL, et al. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008;35:445-447
20. Felice KJ, Relva GM, Conway SR. Further observations on forearm flexor weakness in inclusion body myositis. Muscle Nerve 1998;21:659-661
21. Needham M, Mastaglia FL. Sporadic inclusion body myositis: a continuing puzzle. Neuromusc Disord 2008;18:6-16.
22. Verma A, Bradley WG, Adesina AM, et al. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve 1991;14:470-473
23. Darrow DH, Hoffman HT, Barnes GJ, et al. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg 1992;118:313-317
24. Danon MJ, Perurena OH, Ronan S, et al. Inclusion body myositis associated with systemic sarcoidosis. Can J Neurol Sci 1986;13:334-336 (Pubitemid 17219255)
25. Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998;21:115-117 (Pubitemid 28041688)
26. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-374
27. Hengstman GJ, van Engelen BG, Badrising UA, et al. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis. Ann Neurol 1998;44:423.
28. Garlepp MJ, Laing B, Zilko PJ, et al. HLA associations with inclusion body myositis. Clin Exp Immunol 1994t;98:40-45
29. Fraser DD, Frank JA, Dalakas M, et al. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991;18:1693-1700
30. Sekul EA, Chow C, Dalakas MC. Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis. Neurology 1993;48:863-866 (Pubitemid 27175606)
31. Amato A, Dumitru D. Acquired myopathies. Philadelphia: Hanley and Belfus, 2002.
32. Eisen A, Berry K, Gibson G. Inclusion body myositis (IBM): myopathy or neuropathy? Neurology 1983;33:1109-1114
33. Joy JL, Oh SJ, Baysal AI. Electrophysiological spectrum of inclusion body myositis. Muscle Nerve 1990;13:949-951 (Pubitemid 20341515)
34. Jackson CE, Barohn RJ, Gronseth G, et al. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008;37:473-476
35. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase II/III). J Neurol Sci 1999;169:13-21.
36. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418-424
37. Mendell JR, Sahenk Z, Gales T, et al. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991;48:1229-1234
38. Askanas V, Engel WK, Alvarez RB. Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 1993;43:1265-1267 (Pubitemid 23177742)
39. Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1991;45:1302-1304
40. Rifai Z, Welle S, Kamp C, et al. Ragged red fibers in normal aging and inflammatory myopathy. Ann Neurol 1995;37:24-29
41. Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006;34:406-416
42. Greenberg SA, Watts GD, Kimonis VE, et al. Nuclear localization of valosin-containing protein in normal muscle and muscle affected by inclusion-body myositis. Muscle Nerve 2007;36:447-454
43. Nakano S, Shinde A, Fujita K, et al. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008;18:27-33. (Pubitemid 351173839)
44. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. Journal Neurol Neurosurg Psychiatry 2008;79:1186-1189
45. Salajeyheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of TDP-43 in inclusion body myositis. Muscle Nerve 2009;40:19-36.
46. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16:209-215
47. Greenberg SA, Pinkus GS, Amato AA, et al. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007;35:17-23. (Pubitemid 46052644)
48. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989;20:224-231 (Pubitemid 19081957)
49. Mantegazza R, Andreeta F, Bernasconi P, et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/ beta rearrangements may indicate antigen-driven selection. J Clin Invest 1993;91:2880-2886 (Pubitemid 23182549)
50. O'Hanlon TP, Dalakas MC, Plotz PH, et al. The alpha beta T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. J Autoimmun 1994;7:321-333 (Pubitemid 24190615)
51. Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 2000;123:2030-2039
52. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002;59:1170-1182
53. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyostis. Neurology 2005;65:1782-1787
54. Greenberg SA. A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol 2007;19:536-541
55. Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007;178:547-556 (Pubitemid 46033639)
56. Parker S, Kong SW, Walsh RJ, et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 2009;39:739-753
57. Askanas V, Engel WK. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 2007;19:550-559 (Pubitemid 47530874)
58. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007;69:2008-2019
59. Greenberg SA. Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 2009;9:83-89
60. Dalakas MC. Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation". Ann Neurol 2008;64:15-24.
61. Pruitt JN II, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996;39:139-143
62. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-678 (Pubitemid 40628855)
63. Askanas V, Alvarez RB, Engel WK. beta-Amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993;34:551-560 (Pubitemid 23289406)
64. Askanas V, Engel WK. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003;15:737-744 (Pubitemid 38156300)
65. Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006;66(Suppl 1):S39-48. (Pubitemid 43739983)
66. Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and APP in sIBM:IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008;131:1228-1240
67. Lunemann JD, Schmidt J, Schmid D, et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007;61:476-483 (Pubitemid 46878775)
68. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009;39:b2680.
69. Salajegheh M, Pinkus JL, Nazareno R, et al. Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009 (22 July Epub ahead of print).
70. Oldfors A, Moslemi AR, Fyhr IM, et al. Mitochondrial DNA deletions in muscle fibers in inclusion body myositis. J Neuropathol Exp Neurol 1995;54:581-587
71. Yang CC, Alvarez RB, Engel WK, et al. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Neuroreport 1996;8:153-158
72. Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000;54:1033-1041
73. Chou SM. Inclusion body myositis: a chronic persistent mumps myositis? Hum Pathol 1986;17:765-777
74. Nishino H, Engel AG, Rima BK. Inclusion body myositis: the mumps virus hypothesis. Ann Neurol 1989;25:260-264 (Pubitemid 19085517)
75. Kallajoki M, Hyypia T, Halonen P, et al. Inclusion body myositis and paramyxoviruses. Hum Pathol 1991;22:29-32.
76. Cupler EJ, Leon-Monzon M, Miller J, et al. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brian 1996;119:1887-1893 (Pubitemid 27032621)
77. Semino-Mora C, Dalakas MC. Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol 1998;29:1128-1133 (Pubitemid 28467535)
78. Sunohara N, Nonaka I, Kamei N, et al. Distal myopathy with rimmed vacuole formation. A follow-up study. Brain 1989;112:65-83.
79. Argov Z, Eisenberg I, Grabov-Nardini G, et al. Hereditary inclusion body myopathy: The Middle Eastern genetic cluster. Neurology 2003;60:1519-1523 (Pubitemid 36554816)
80. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/ N-N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myositis. Nat Genet 2001;29:83-87 (Pubitemid 32801815)
81. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004;36:377-381 (Pubitemid 38437260)
82. Kimonis VE, Mehta SG, Fulchiero EC, et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet 2008;146A:745-757
83. Martinsson T, Oldfors A, Darin N, et al. Autosomal dominant myopathy: Missense mutation (Glu-706 to Lys) in the myosin heavy IIa gene. Proc Natl Acad Sci USA 2000;97:14614-14619 (Pubitemid 32016624)
84. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994;44:1516-1518 (Pubitemid 24247450)
85. Dalakas MC. Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 2004;17:561-567
86. Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993;94:379-387
87. Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993;72:225-235 (Pubitemid 23246251)
88. Badrising UA, Maat-Shieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51:369-372 (Pubitemid 34206293)
89. Lindberg C, Trysberg E, Tarkowski A, et al. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003;61:260-262 (Pubitemid 36875317)
90. Quartuccio L, De Marchi G, Scott CA, et al. Treatment of inclusion body myositis with cyclosporine-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 2007;25:246-251 (Pubitemid 46851428)
91. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-879 (Pubitemid 23150554)
92. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-716 (Pubitemid 27120112)
93. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327 (Pubitemid 32144142)
94. Walker MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-28 (Pubitemid 30162508)
95. Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006;66(Suppl 1):S123-4. (Pubitemid 43739998)
96. Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001;57:1566-1570
97. Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004;63:718-720
98. Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002;58:1081-1087
99. Johnson L, Edwards D, Walters S, et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromusc Dis 2007;8:187-194 (Pubitemid 47052000)
100. Cudkowicz ME, Shefner JM, Simpson E, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008;38:837-844 (Pubitemid 351915317)
101. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008;105:2052-2057
102. Kitazawa M, Trinh DN, Laferla FM, et al. Inflammation induced tau pathology in inclusion body myositis model via glycogen synthetase kinase-3beta. Ann Neurol 2008;64:15-24.